Trial Profile
An observational longitudinal retrospective study evaluated the impact of treatment with insulin degludec (IDeg) on mean blood glucose and glycemic variability in non-critical hospitalized patients with and without type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2018
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- 28 May 2018 New trial record
- 17 May 2018 Results published in the Advances in Therapy